… quadrivalent HPV vaccine were effective against genital warts in our population. Moreover,
with low vaccine coverage the incidence of genital warts decreased only in the vaccinated. …

… HPV-related disease. We provide nationwide, real-world data on the risk of genital warts (GWs)
after <3 vaccine … against GWs with the quadrivalent HPV vaccine (HPV types 6, 11, 16, …

… To assess the effectiveness of the HPV vaccines in preventing genital warts (GW) in women
aged 14–23 years and to estimate the incidence of GW in the whole population aged from …

… of HPV vaccine in preventing the relapse of ano-genital warts. The results suggest that HPV
vaccination does not provide secondary benefit in patients with previous ano-genital warts. …

… Near elimination of genital warts in Australia predicted with extension of human
papillomavirus vaccination to males. Sex Transm Dis 2013; 40:833-5; PMID:24113401; http://dx.doi.org/…

… , vaginal and anal cancer as end points in their phase III trials [6], [7], [8]. HPV 6 and 11 cause
85% of all genital warts … the quadrivalent HPV vaccine and later in the nonavalent vaccine. …

… of a nonavalent HPV vaccination for treatment of genital warts because the vaccine may
be beneficial as an alternative noninvasive treatment of recalcitrant genital warts. However, …

… human papillomavirus (HPV) vaccine has been assumed to give protection against genital
warts (GW) as well as cervical cancer. Our main question was whether HPV vaccine has any …

… of all cancers are HPV associated with HPV 16 and 18 accounting … Genital warts caused
by HPV 6 and 11 have a lifetime risk of acquisition of 10%. HPV vaccines are subunit vaccines …

… HPV vaccination program in 2008 using the quadrivalent HPV vaccine, which protects against
HPV … The quadrivalent vaccine was chosen through a tender process. Since January 2009…